garadacimab-gxii

garadacimab-gxii (ANDEMBRY) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

ANDEMBRY is a marketed brand name for garadacimab-gxii. Check FDA Drugs@FDA for the current US label holder and prescribing information.

garadacimab-gxii has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.